Navigating management of localized prostate cancer in the geriatric population.

Crit Rev Oncol Hematol

The Minimally Invasive Urology Institute, The Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA; Warren Alpert Medical School of Brown University, Providence, RI, USA. Electronic address:

Published: December 2024

Prostate cancer (PCa) is highly prevalent among aging men and a significant contributor to global mortality. Balancing early detection and treatment of "clinically significant" disease with avoiding over-detection and overtreatment of slow-growing tumors is challenging, especially for elderly patients with competing health risks and potentially aggressive disease phenotypes. This review emphasizes the importance of individualized approaches for diagnosing and treating PCa in geriatric patients. Active surveillance and watchful waiting are common strategies, while surgical interventions are less frequent but considered based on comorbidities, disease risk, and patient preferences. Radiotherapy, often combined with androgen deprivation therapy, is typical for higher-risk cases, and focal therapy is emerging to reduce morbidity. An inclusive approach combining advanced diagnostics, life expectancy considerations, and minimally invasive interventions can improve decision-making. Integrating multidisciplinary strategies with better risk stratification and less invasive options can significantly enhance care and outcomes for elderly patients with significant PCa.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2024.104600DOI Listing

Publication Analysis

Top Keywords

prostate cancer
8
elderly patients
8
navigating management
4
management localized
4
localized prostate
4
cancer geriatric
4
geriatric population
4
population prostate
4
cancer pca
4
pca highly
4

Similar Publications

The cascade of events leading to tumor formation includes induction of a tumor supporting neovasculature, as a primary hallmark of cancer. Developing vasculature is difficult to evaluate but can be captured using microfluidic chip technology and patient derived cells. Herein, we established an approach to investigate the mechanisms promoting tumor vascularization and vascular targeted therapies via co-culture of cancer spheroids and endothelial cells in a three dimensional environment.

View Article and Find Full Text PDF

Adaptive Treatment of Metastatic Prostate Cancer Using Generative Artificial Intelligence.

Clin Med Insights Oncol

January 2025

Ted Rogers School of Information Technology Management, Toronto Metropolitan University, Toronto, ON, Canada.

Despite the expanding therapeutic options available to cancer patients, therapeutic resistance, disease recurrence, and metastasis persist as hallmark challenges in the treatment of cancer. The rise to prominence of generative artificial intelligence (GenAI) in many realms of human activities is compelling the consideration of its capabilities as a potential lever to advance the development of effective cancer treatments. This article presents a hypothetical case study on the application of generative pre-trained transformers (GPTs) to the treatment of metastatic prostate cancer (mPC).

View Article and Find Full Text PDF

Ultrasound radiomics model based on grayscale transrectal ultrasound-guided biopsy for diagnosing prostate cancer and predicting distant metastasis.

Int Urol Nephrol

January 2025

Department of Ultrasound, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, No. 2 Jiefang Road, Xiling District, Yichang, Hubei, China.

Objective: A prostate ultrasound (US) imaging omics model was established to assess its effectiveness in diagnosing prostate cancer (PCa), predicting Gleason score (GS), and determining the likelihood of distant metastasis.

Methods: US images of patients with prostate pathology confirmed by biopsy or surgery at our hospital were retrospectively analyzed. Regions of interest (ROI) segmentation, feature extraction, feature screening, and the construction and training of the radiomics model were performed.

View Article and Find Full Text PDF

Prostate cancer (PCa) is the second leading cause of cancer-related mortality among men in the United States. While PCa initially responds to androgen deprivation therapy, a significant portion progresses to castration-resistant PCa. Approximately 20-25% of these cases acquire aggressive neuroendocrine (NE) features, ultimately leading to neuroendocrine prostate cancer (NEPC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!